港股异动 | 君实生物-B收涨逾3% A股科创板上市已通过上海证监局辅导验收
格隆汇9月17日丨君实生物-B(1877.HK)今日收报30.7港元,逆市涨3.02%,成交3507万港元,最新总市值240.7亿港元。君实生物-B昨晚发公告称,公司A股科创板上市已通过证监会上海监管局的辅导验收,中金公司为其科创板上市辅导工作的辅导机构。此外,拓益*(通用名:特瑞普利单抗注射液)治疗晚期膀胱尿路上皮癌的关键注册临床研究已完成全部患者入组。据悉,拓益*作为中国批准上市的首个国产以PD-1为靶点的单抗药物,获得国家科技重大专项项目支持。中信建投最新发研报指,君实生物-B目前特瑞普利单抗销售情况良好,加上公司后续研发管线推进,未来具有较大成长空间,维持“买入”评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.